R01 / Beijing Anjianxi Bio-Medical - LARVOL DELTA

A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors. (ASCO 2025) - P1 | "R01 has shown an extremely excellent safety profile, favorable pharmacokinetics, and very encouraging activity across a broad range of tumor types. Recruitment into the phase-2 part of the study is ongoing. Clinical trial information: ChiCTR2500095101."

Clinical • IO biomarker • Metastases • P1 data • Anemia • Colorectal Cancer • Fatigue • Head and Neck Cancer • Leukopenia • Lung Cancer • Nasopharyngeal Carcinoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thrombocytopenia • HIF1A • KRAS • PD-L1 • TP53